Pre-market Movers For Sept 10 (CAG, CROX, FOLD, FIVE, NBIX, CCXI, URBN, THRX)

(RTTNews) - Gainers:

Amicus Therapeutics, Inc. (FOLD) is up 17 percent to $3.00. The company entered a collaboration with Biogen Idec (BIIB) to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease. Biogen Idec will be responsible for funding all discovery, development, and commercialization activities.

Five Below, Inc. (FIVE) following 12 percent to $46.17 the release of its quarterly results.

Decliners:

ConAgra Foods, Inc. (CAG) is down 2 percent to $32.81. The company lowered its fiscal 2014 earnings guidance, reflecting lower-than-planned fiscal first-quarter earnings per share. The company said challenging industry conditions have weighed on overall results and that the softer-than-planned first-quarter comparable EPS performance principally relates to the Consumer Foods segment, where difficult conditions for some branded retail categories and some customers have negatively impacted sales and profits.

Crocs, Inc. (CROX) is falling 7 percent to $12.55. The company lowered its third quarter guidance citing continued weakness in its Americas region where at once orders in the wholesale channel, as well as performance in the direct to consumer channel, were below prior expectations.

Neurocrine Biosciences Inc. (NBIX) is plunging 26 percent to $12.25. The company announced that the 50mg dose of NBI-98854, a small molecule VMAT2 inhibitor in development for tardive dyskinesia, did not meet the primary endpoint in the Phase IIb Kinect study while the 100mg dose showed a statistical and clinically significant improvement.

ChemoCentryx, Inc. (CCXI) is down 19 percent to $6.70. The company announced interim data from an ongoing Phase II study in patients with diabetic nephropathy, also known as diabetic kidney disease, with CCX140. CCX140 is an inhibitor of the chemokine receptor known as CCR2, and the drug candidate is wholly owned by the company.

Urban Outfitters Inc. (URBN) is down 6 percent to $39.97.

Trading halt:

Trading in shares of Theravance Inc. (THRX) was halted. The Pulmonary-Allergy Drugs Advisory Committee of the FDA will meet today to discuss the new molecular entity New Drug Application for umeclidinium bromide and vilanterol dry powder for inhalation (proposed trade name ANORO ELLIPTA), for the long-term, once-daily, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

Trading in shares of Tower Financial Corp. (TOFC) was halted. Old National Bancorp (ONB) has agreed to acquire the company in transaction valued at about $107.7 million. As per the terms of the merger agreement, shareholders of Tower Financial will receive 1.20 shares of Old National Bancorp common stock and $6.75 in cash (fixed) for each share.